MilliporeSigma
HomeGene Expression & SilencingTRC Design and pLKO.1 Vector FAQs

TRC Design and pLKO.1 Vector FAQs

MISSION® shRNA

pLKO.1 puro sequence

MISSION® shRNA Vector Map

Why is the U6 promoter used?

The human U6 promoter (a pol III promoter) is used to drive expression of the shRNA hairpin. Expression using pol III promoters is optimal for producing shRNAs due to precise initiation and termination of transcription. TRC chose U6 based on experimental data showing excellent efficiency when compared to another efficient pol III promoter (H1).

The shRNA was cloned into the AgeI and EcoRI sites. The individual hairpin sequences can be found on our website as well.

No, the TRC1 vector, pLKO.1-puro, does not contain WPRE (Woodchuck Posttranscriptional Regulatory Element). It is contained in the TRC2 vector, TRC2-pLKO-puro. WPRE is known for its ability to enhance transcription of transgenes.

We recommend Pvu II. Restriction digest with Pvu II results in three bands; however, clones with an additional Pvu II site in the hairpin insert will produce four bands: 2513 bp, 2325 bp, 1478 bp and 776 bp.

PVU-II

The band sizes following digestion with Pvu II of the shRNA vectors are 3803 bp, 2513 bp, and 776 bp.

The larger the insert put into pLKO.1 vector, the lesser the functional titer of the produced lentivirus. We generally suggest the total size of pLKO.1 be less than 9 kb.

Yes. TRC 1.5 has the same vector backbone as TRC1.

Yes, TRC1 and TRC1.5 share the same vector backbone. TRC1.5 has all the content you love with the vector backbone you trust, now with even more coverage. TRC1.5 is the largely extended version of the old TRC1 library. All TRC1.5 controls will work with TRC1 clones.

They are not different. TRC 1.5 has the same vector backbone as TRC1. TRC1.5 has all the content you love with the vector backbone you trust, now with even more coverage. There is no difference between TRC1 and TRC1.5, except for the extended coverage.

Contact Us

For questions about the library, pricing and quotes or other concerns, please e-mail us .

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?